News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DiaKine Therapeutics, Inc.'s Lead Compound in Phase 2 Clinical Trial


10/14/2008 11:09:44 AM

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--DiaKine Therapeutics, developers of drugs designed to cause diabetes to go into remission, announced today that a Phase 2 Clinical Trial with the Company’s lead drug candidate, Lisofylline (LSF), is underway.

Read at BioSpace.com

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES